Astria Therapeutics Stock Piotroski F Score
| ATXS Stock | USD 9.00 0.64 6.64% |
Astria | Piotroski F Score |
At this time, it appears that Astria Therapeutics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Unavailable
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | No Change |
Astria Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Astria Therapeutics is to make sure Astria is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Astria Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Astria Therapeutics' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0223 | 0.0251 |
|
| |||||
| Total Current Liabilities | 6.2 M | 11.6 M |
|
| |||||
| Total Assets | 267.4 M | 254.7 M |
|
| |||||
| Total Current Assets | 263.5 M | 250.9 M |
|
|
Astria Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Astria Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Astria Therapeutics in a much-optimized way.
Click cells to compare fundamentals
About Astria Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Astria Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Astria Therapeutics from analyzing Astria Therapeutics' financial statements. These drivers represent accounts that assess Astria Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Astria Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 66.2M | 39.3M | 48.1M | 217.7M | 231.3M | 242.9M | |
| Enterprise Value | 58.5M | 15.4M | (38.0M) | 198.1M | 56.0M | 32.5M |
About Astria Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astria Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astria Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astria Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Astria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Astria Stock
| 0.58 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.51 | ELYM | Eliem Therapeutics | PairCorr |
| 0.47 | CGC | Canopy Growth Corp Trending | PairCorr |
The ability to find closely correlated positions to Astria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astria Therapeutics to buy it.
The correlation of Astria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Astria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Astria Therapeutics Altman Z Score, Astria Therapeutics Correlation, Astria Therapeutics Valuation, as well as analyze Astria Therapeutics Alpha and Beta and Astria Therapeutics Hype Analysis. For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Astria Stock analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Astria Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astria Therapeutics. If investors know Astria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astria Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Return On Assets (0.17) | Return On Equity (0.31) |
The market value of Astria Therapeutics is measured differently than its book value, which is the value of Astria that is recorded on the company's balance sheet. Investors also form their own opinion of Astria Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Astria Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astria Therapeutics' market value can be influenced by many factors that don't directly affect Astria Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astria Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Astria Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.